SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vanta Bioscience forays into Clinical Research

30 Jul 2018 Evaluate

Vanta Bioscience has forayed into Clinical Research through a 100% subsidiary. The clinical research business will begin contributing to the top-line in the last quarter of the current financial year.

The company is projecting to add revenue of Rs 250 crore in the fifth year through clinical research services. Major activities covered under the clinical services include bio-equivalence studies in healthy human volunteers, patient volunteers, bioanalytical services and clinical trials from Phase I to Phase IV.

Vanta Bioscience is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries.

Vanta Bioscience Share Price

25.29 0.00 (0.00%)
06-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internatl. 409.10
Indegene 494.25
CMS Info Systems 264.05
JITF Infralogistics 294.85
Sagility 40.37
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: